Skip to content

The US Food and Drug Administration (FDA) has approved Abbott’s Eterna Spinal Cord Stimulation (SCS) System for the treatment of chronic pain.

The Eterna SCS system is said to be the smallest implantable, rechargeable system currently on the market for this indication.

It uses the company’s low-dose BurstDR stimulation, SCS waveform technology that mimics the natural firing patterns found in the brain to provide superior pain relief.

The company stated that SCS technology has demonstrated 23% greater pain reduction compared to traditional wave technology approaches.

It also noted that the Eterna SCS system was developed based on extensive studies with patients, physicians and caregivers to understand the unmet needs of chronic pain patients.

Studies have shown that people prefer smaller implants with less need to charge the device daily or weekly.

The Eterna SCS system can be wirelessly charged less than five times per year under normal use, which is considered the lowest charging load compared to other SCS systems.

Abbott neuromodulation Vice President Pedro Malha said: “At Abbott, we provide products and solutions with the goal of simplifying healthcare, improving clinical outcomes and providing the best experience for people with chronic pain. As we progress on this commitment, Eterna is the next big leap forward.

“Eterna is the smallest rechargeable spinal cord stimulator on the market, provides the longest therapy between charges and offers an optimized charging experience, all key features when choosing the best overall system.”

The company said the new neuromodulation device uses its TotalScan MRI technology to provide full-body MRI scans for chronic pain patients in need of improved diagnosis and wellness.

In addition, a patient-focused mobile app displays real-time battery life and charge status updates for the Eterna SCS system on a personal or Abbott-provided specific Apple device.


Leave a Reply

Your email address will not be published. Required fields are marked *